User login
Vismodegib is an oral small-molecule inhibitor of smoothened homologue protein (SMO), a component of the hedgehog signaling pathway that has been shown to have activity in advanced basal cell carcinoma (BCC). In early 2012, vismodegib was approved by the Food and Drug Administration for treatment of adult patients with metastatic BCC (mBCC) who are not candidates for radiation therapy and adult patients with locally advanced BCC that has recurred following surgery or who are not candidates for surgery or radiation therapy1…
*Click on the links to the left of this introduction for a PDF of the full article and an accompanying Commentary.
Vismodegib is an oral small-molecule inhibitor of smoothened homologue protein (SMO), a component of the hedgehog signaling pathway that has been shown to have activity in advanced basal cell carcinoma (BCC). In early 2012, vismodegib was approved by the Food and Drug Administration for treatment of adult patients with metastatic BCC (mBCC) who are not candidates for radiation therapy and adult patients with locally advanced BCC that has recurred following surgery or who are not candidates for surgery or radiation therapy1…
*Click on the links to the left of this introduction for a PDF of the full article and an accompanying Commentary.
Vismodegib is an oral small-molecule inhibitor of smoothened homologue protein (SMO), a component of the hedgehog signaling pathway that has been shown to have activity in advanced basal cell carcinoma (BCC). In early 2012, vismodegib was approved by the Food and Drug Administration for treatment of adult patients with metastatic BCC (mBCC) who are not candidates for radiation therapy and adult patients with locally advanced BCC that has recurred following surgery or who are not candidates for surgery or radiation therapy1…
*Click on the links to the left of this introduction for a PDF of the full article and an accompanying Commentary.